The potential of lasmiditan in migraine

Lasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT(1F)) agonist, is the first drug in its class and is lacking triptan-like vasoactive properties. The US Food and Drug Administration (FDA) has recently approved lasmiditan for the acute treatment of migraine in adults based on posit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ther Adv Neurol Disord
Hauptverfasser: Mecklenburg, Jasper, Raffaelli, Bianca, Neeb, Lars, Sanchez del Rio, Margarita, Reuter, Uwe
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2020
Schlagworte:
Review
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7739205/
https://ncbi.nlm.nih.gov/pubmed/33403005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756286420967847
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge